糖基化终末产物对3T3-L1脂肪细胞脂联素分泌的影响

目的糖基化终末产物(Advanced glycation end products,AGE)对3T3-L1脂肪细胞脂联素(adiponectin,APN)分泌的影响。方法3T3-L1小鼠前脂肪细胞体外培养并诱导分化为成熟的脂肪细胞,以PBS和BSA作为阴性对照,用含不同浓度梯度(50μg/ml、100μg/ml、150μg/ml)AGE的培养液对成熟的脂肪细胞体外培养48h,收集细胞和上清液,用RT-PCR方法检测脂联素mRNA的表达,ELISA方法检测培养液中脂联素蛋白的分泌情况。结果AGE干预组脂联素的表达在mRNA和蛋白水平较对照组均明显下降(P<0.05),并且随着AGE浓度的升高脂联素的合成和分泌逐渐减少,其中100μg/ml、150μg/ml AGE干预组脂联素的减少较对照组有显著差异(P<0.001)。结论糖基化终末产物能够通过抑制3T3-L1细胞脂联素mRNA的合成,近而抑制脂联素的分泌,且这种抑制呈浓度依赖性。     

脂联素siRNA对3T3-L1细胞基础葡萄糖转运的影响

目的：构建携带小鼠脂联素（Acrp30）siRNA腺病毒载体,并检测其对小鼠脂肪细胞Acrp30表达以及对3T3-L1脂肪细胞基础葡萄糖转运的影响。方法：设计并化学合成小鼠脂肪细胞Acrp30 siRNA片断,将其亚克隆入AdEaxy XL腺病毒载体系统,在293细胞内包装扩增为重组腺病毒。用此重组腺病毒感染3T3-L1脂肪细胞,用RT-PCR和ELISA检测其Acrp30 mRNA和蛋白表达。采用2Deoxy-[3H]D—glucose掺入法测定脂肪细胞葡萄糖转运。结果：设计并构建了小鼠Acrp30基因特异性siRNA腺病毒载体,该载体感染脂肪细胞后,能显著抑制Acrp30 mRNA和蛋白表达,影响3T3-L1脂肪细胞基础葡萄糖的转运,与对照组相比,差异有显著性意5C（P〈0．05）。结论：构建的Acrp30基因特异性siRNA腺病毒载体能有效的抑制脂联素在3T3-L1脂肪细胞中的表达,从而影响3T3-L1脂肪细胞基础葡萄糖转运。     

人参皂苷Rb1、Rc对大鼠胚胎脑发育及GPx基因表达的影响

目的观察人参皂苷Rb1、Rc对sD大鼠胚胎脑发育及谷胱甘肽过氧化物酶（61utathione peroxidase,GPx）基因表达的影响。方法实验选用全胚胎体外培养方法,根据Van Maele-Fabry等制定的形态学分析系统进行形态学检测,实验随机分为对照组、人参皂苷Rbl（10,45和90ug／ml）组和人参皂苷Rc（10,45和90ug／ml）组,采用半定量RT—PCR分析人参皂苷Rb1和人参皂苷Rc对胚胎谷胱甘肽过氧化物酶基因表达的影响。结果与对照组比较,人参皂苷Rb1（10,45和90ug／ml）组胚胎脑、前脑、中脑与后脑的长度值没有统计学意义（P〉0．05）;与对照组比较,人参皂苷Rc（10,45和90ug／m1）组前脑、中脑与后脑的长度值显著增加（P〈0．05）。RT—PCR结果显示,人参皂苷Rb1（10,45和90ug／ml）组cGPx与phGPx mRNA的表达水平与对照组比较均没有统计学意义（P〉O．05）,而pGPxmRNA的表达水平在浓度50和100ug／ml时显著增加（P〈0．05）。人参皂苷Rc（10,45和90ug／ml）组cGPx与phGPxmRNA的表达水平与对照组比较均没有统计学意义（P〉0．05）,而pGPxmRNA的表达水平在各种浓度的Rc作用后都增加,且在溶度10和45ug／ml浓度时增加显著（P〈0．05）。结论一定剂量的人参皂苷Rc能促进胚胎脑的发育,一定剂量的人参皂苷Rb1、Rc能明显增强胚胎脑pGPx mRNA的表达水平。     

运动对老年肥胖大鼠脂联素的影响

目的：探讨运动对老年肥胖大鼠内脏脂肪组织脂联素mRNA和蛋白质表达、血浆脂联素浓度及胰岛素抵抗的影响。方法：取雄性SD大鼠,鼠龄21 d,分青春期、壮年期和老年期三个阶段喂养高脂饲料（脂肪率为36.3%~40.0%）,建立老年肥胖模型。鼠龄达到60周后,取自然生长老年大鼠随机分为对照组（C）和老年运动组（AE）,n=6;取老年肥胖大鼠随机分为肥胖对照组（OC）和肥胖运动组（OE）,n=6。动物跑台坡度0°,运动速度及时间为（15 m/min×15 min）,4组/次,组间休息5 min,每次共运动60 min,5次/周,持续运动8周。8周后,检测内脏脂肪组织脂联素mRNA和蛋白质表达,测定血糖、血浆脂联素浓度和胰岛素浓度,计算胰岛素抵抗。结果：运动干预后,与对照组比较,肥胖对照组大鼠脂联素mRNA和蛋白质表达显著减低,血糖浓度和胰岛素抵抗明显增高;而老年运动组大鼠脂联素mRNA和蛋白质表达显著增高。与肥胖对照组大鼠比较,肥胖运动组大鼠脂联素mRNA和蛋白质表达显著增高、血浆脂联素水平增高,血糖浓度和胰岛素抵抗明显减低。结论：老年肥胖大鼠内脏脂肪组织脂联素mRNA和蛋白质表达均降低,伴随胰岛素抵抗、血糖升高。运动能显著增加其内脏脂肪组织脂联素mRNA和蛋白质表达,升高血浆脂联素水平,改善胰岛素抵抗,降低血糖。     

黄体酮对3T3-L1脂肪前体细胞成脂分化后细胞中UCP2基因表达的影响

目的：观察体外培养条件下3T3-L1脂肪前体细胞诱导分化成的成熟脂肪细胞中解偶联蛋白2（UCP2）mRNA表达水平及黄体酮对其表达的影响。方法：体外培养3T3-L1脂肪细胞,在诱导3T3．L1脂肪细胞分化成熟后,经不同黄体酮浓度10μm／25μM／50μM／75μM/100μM刺激后,抽提总RNA,用RT—PCR检测UCP2mRNA的表达。结果：黄体酮会促进成熟脂肪细胞中UCP2mRNA的表达,（P〈0．05）其中25μM浓度刺激下UCP2mRNA表达量最高。结论：体外培养中,黄体酮对成熟脂肪细胞中UCP2mRNA的表达与调控具有一定的影响。     

低氧促进大鼠肺动脉平滑肌细胞Periostin表达及其信号转导机制

观察低氧对大鼠肺动脉平滑肌细胞（pulmonary artery smooth muscle cells,PASMCs）Periostin表达的影响及其相关信号转导机制。胶原酶I法原代培养PASMCs,经低氧（5％O2）分别处理PASMCs2,6,12,24h后,RT-PCR和Western blot法检测Periostin mRNA和蛋白表达。加入PI3K/Akt通路特异性抑制剂LY294002（10μmol／L）进行干预,Western blot分析比较不同条件下低氧处理24h后大鼠PASMCs中Periostin和Akt／P-Akt的蛋白表达。结果表日月,与常氧组比较,低氧处理6h组、12h组和24h纽Periostin mRNA和蛋白的表达均显著上升（P〈0．05,P〈0．01）,低氧处理后的PASMCs中Periostin mRNA和蛋白的表达逐渐升高：低氧处理2h组无显著差异（P〉0．05）。用LY294002对PASMCs处理,并低氧24h后,Periostin的表达被显著抑制（P〈0．01）,细胞P-Akt的表达下调（P〈0．05）,总Akt的蛋白表达没有明显差异（P〉0．05）。推测低氧可诱导大鼠PASMCs中Periostin mRNA和蛋白的表达上调。低氧可能通过激活P13K/Akt通路促进Akt的磷酸化,进而使Periostin在PASMCs中过表达,提示Periostin在低氧性PASMCs增殖过程中可能起着重要作用。     

大鼠胰岛素抵抗形成中脂联素受体基因表达及运动的影响

目的:检测SD大鼠脂联素受体的分布,观察大鼠胰岛素抵抗(IR)形成中脂联素受体(Adipok)基因表达及运动的影响。方法:46只雄性SD大鼠随机分为4组(n=12),以高脂膳食喂养诱导IR,同时运动组实施10周游泳运动干预。结果:AdipoR1/R2mRNA分别在骨骼肌和肝脏高表达(P<0.05);H组骨骼肌AdipoR1和肝脏AdipoR2mRNA表达显著低于C组(P<0.05)。结论:骨骼肌和肝脏AdipoR1/R2mRNA表达的下调可能是高脂大鼠IR形成的机制之一,未观察到运动干预的显著影响。     

胰岛素对阿尔茨海然病大鼠血浆血小板活化因子及海马突触可塑性的影响

目的：探讨胰岛素对阿尔茨海默病（AD）大鼠血浆血小板活化因子（PAF）及海马突触可塑性的影响。方法：将30只SD大鼠随机分为治疗组（10只）、模型组（10只）、假手术组（10只）,采用侧脑室注射链脲霉素（STZ）建立AD大鼠模型。治疗组大鼠皮下注射胰岛素（0．1U／kg）,模型组及假手术组大鼠皮下注射等体积的生理盐水（1mL／kg）。通过Morris’s水迷宫实验评估各组大鼠的认知功能,酶联免疫吸附法测定各组大鼠的血浆PAF含量,免疫印迹法检测大鼠海马突触素的表达。结果：治疗4周后,模型组大鼠连续4天水迷宫的潜伏期均显著长于假手术组大鼠（P〈0．05）,而治疗组大鼠第2、3、4天水迷宫潜伏期均较模型组显著缩短（P〈0．05）,但仍长于假手术组大鼠（P〈0．05）;模型组大鼠的血浆PAF含量和海马突触素的表达均显著高于假手术组,而治疗组大鼠的血浆PAF含量和海马突触素的表达均显著低于模型组（P〈0．05）,差异均有统计学意义（P〈0．05）。结论：皮下注射胰岛素可改善AD大鼠的认知功能,这可能与其下调AD大鼠血浆PAF水平以及保护突触的可塑性有关。     

褪黑素受体激动剂改善高糖高脂喂养大鼠脂联素敏感性

目的观察褪黑素受体激动剂（NEU-P11）对高糖高脂饲养大鼠脂联素敏感性的影响。方法将30只SD大鼠随机分为对照组（CD组）,高糖高脂组（HFSD组）,褪黑素组（Mel组）,褪黑素受体激动剂组（NEU-P11组）。CD组饲以正常饲料;其余3组饲以高糖高脂饲料。6个月后,给药治疗2个月。治疗期间,Mel组每天注射Mel（4mg／kg）;NEU—P11组每天注射NEU-P11（10mg／kg）;CD组以及HFSD组注射生理盐水（5ml／kg）。测定糖脂代谢指标并做口服葡萄糖耐量实验（oral glucose tolerant test,OG-TY）,Western印迹检测脂联素（adiponectin,APN）在脂肪组织及脂联素受体（AdipoR）在骨骼肌组织中的表达变化。结果高糖高脂饮食可诱导SD大鼠产生胰岛素抵抗,脂联素表达增加。Neu-P11治疗后,胰岛素敏感性增强．脂联素表达降低至正常水平。结论Neu-P11能提高胰岛素敏感性,改善脂联素抵抗。     

脂联素siRNA对3T3-L1细胞基础葡萄糖转运的影响(英文)

目的:构建携带小鼠脂联素(Acrp30)siRNA腺病毒载体,并检测其对小鼠脂肪细胞Acrp30表达以及对3T3-L1脂肪细胞基础葡萄糖转运的影响。方法:设计并化学合成小鼠脂肪细胞Acrp30 siRNA片断,将其亚克隆入AdEaxy XL腺病毒载体系统,在293细胞内包装扩增为重组腺病毒。用此重组腺病毒感染3T3-L1脂肪细胞,用RT-PCR和ELISA检测其Acrp30 mRNA和蛋白表达。采用2 Deoxy-[3H]D-glucose掺入法测定脂肪细胞葡萄糖转运。结果:设计并构建了小鼠Acrp30基因特异性siRNA腺病毒载体,该载体感染脂肪细胞后,能显著抑制Acrp30 mRNA和蛋白表达,影响3T3-L1脂肪细胞基础葡萄糖的转运,与对照组相比,差异有显著性意义(P<0.05)。结论:构建的Acrp30基因特异性siRNA腺病毒载体能有效的抑制脂联素在3T3-L1脂肪细胞中的表达,从而影响3T3-L1脂肪细胞基础葡萄糖转运。     

Adiponectin and leptin are secreted through distinct trafficking pathways in adipocytes

Adiponectin and leptin are two adipokines secreted by white adipose tissue that regulate insulin sensitivity. Previously we reported that adiponectin but not leptin release depends on GGA-coated vesicle formation, suggesting that leptin and adiponectin may follow different secretory routes. Here we have examined the intracellular trafficking pathways that lead to the secretion of these two hormones. While adiponectin and leptin displayed distinct localization in the steady-state, treatment of adipocytes with brefeldin A inhibited both adiponectin and leptin secretion to a similar level, indicating a common requirement for class III ADP-ribosylating factors and an intact Golgi apparatus. Adiponectin secretion was significantly reduced by endosomal inactivation in both 3T3L1 and rat isolated adipocytes, whereas this treatment had no effect on leptin secretion. Importantly, endosomal inactivation completely abolished the insulin stimulatory effect on adiponectin release in rat adipocytes. Confocal microscopy studies revealed colocalization of adiponectin with endogenous rab11 a marker for the recycling endosome, and with expressed rab5-GFP mutant (rab5Q75L) a marker for the early endosome compartment. Colocalization of adiponectin and rab5Q75L was increased in endosome inactivated cells. Consistent with these findings adiponectin secretion was reduced in cells expressing mutants of Rab11 and Rab5 proteins. In contrast, expression of an inactive (kinase dead) mutant of Protein Kinase D1 moderately but significantly inhibited leptin secretion without altering adiponectin secretion. Taken together, these results suggest that leptin and adiponectin secretion involve distinct intracellular compartments and that endosomal compartments are required for adiponectin but not for leptin secretion.     

Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes

Adiponectin is intimately involved in the regulation of insulin sensitivity, carbohydrate and lipid metabolism, and cardiovascular functions. The circulating concentration of adiponectin is decreased in obesity and Type 2 diabetes. The present study attempts to elucidate the mechanisms underlying the regulation of adiponectin secretion and expression in rat primary adipocytes. The beta-agonist, isoprenaline, decreased adiponectin secretion and expression in a dose-dependent manner in primary adipocytes. Importantly, such an inhibitory effect could be blocked by insulin. The opposing effects of isoprenaline and insulin could be explained by differential regulation of intracellular cAMP levels, since cAMP analogues suppressed adiponectin secretion and expression in a fashion similar to isoprenaline, and insulin blocked the inhibitory effects of the cAMP analogue hydrolysable by PDE (phosphodiesterase). A specific PDE3 inhibitor, milrinone, and PI3K (phosphoinositide 3-kinase) inhibitors abolished the effects of insulin on adiponectin secretion and expression. In the same studies, leptin secretion and expression displayed a similar pattern of regulation to adiponectin. We conclude that insulin and beta-agonists act directly at the adipocytes in opposing fashions to regulate the production of adiponectin and leptin, and that a PI3K-PDE3B-cAMP pathway mediates the effects of insulin to restore beta-agonist/cAMP-suppressed secretion and expression of these two adipokines.     

Potential interaction of brain natriuretic peptide with hyperadiponectinemia in preeclampsia

Adiponectin was reported recently to have roles in the pathophysiology of preeclampsia. Moreover, elevation of adiponectin and brain natriuretic peptide (BNP) has been observed in preeclampsia. We examined the possible links between adiponectin and BNP in the pathophysiology of preeclampsia. We performed a cross-sectional study in 56 preeclampsia patients and 56 controls matched for gestational age and body mass index. The BNP, leptin, and adiponectin levels were measured by ELISA, and their mRNA expressions were evaluated in omental adipose tissue by real-time PCR. The effects of BNP on adiponectin and leptin mRNA expression and secretion were investigated in primary cultures of adipocytes from obese and normal-weight women. The BNP, adiponectin, and leptin levels were significantly higher in preeclampsia patients compared with controls. The adiponectin level was increased significantly in normal-weight preeclampsia patients compared with overweight preeclampsia patients. Adiponectin mRNA expression was increased significantly in adipose tissues of preeclampsia patients compared with controls and was also increased significantly in normal-weight preeclampsia patients compared with overweight preeclampsia patients, whereas leptin was not. BNP and adiponectin showed significant positive correlations in both normal-weight and overweight preeclampsia patients. BNP had a significantly weaker effect on adiponectin in overweight compared with normal-weight preeclampsia patients. Moreover, BNP had a weaker effect on adiponectin production in adipocytes from overweight women compared with adipocytes from normal-weight women using primary culture of human adipocytes. These data suggested that BNP may play a role in hyperadiponectinemia of preeclampsia patients. The weaker effect of BNP on adiponectin production may participate in the pathophysiology of overweight preeclampsia patients.     

Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight

Adiponectin is an adipocytokine with profound anti-diabetic and anti-atherogenic effects. Even though adiponectin expression is restricted to adipocytes, serum levels are paradoxically decreased in obesity. We characterized how adiponectin expression and regulation relates to adipocyte differentiation in a human adipocyte cell culture model. Adiponectin was not expressed by human preadipocytes. Differentiation into adipocytes was necessary to induce an increasing expression of adiponectin (359 +/- 64-fold, P < 0.001) in parallel to an increasing expression of adipocyte differentiation markers. Adiponectin protein synthesis and secretion occurred specifically in mature adipocytes and may thus serve as a distinctive marker of adipocyte differentiation. Addition of serum during the course of differentiation as well as acutely to mature adipocytes significantly and concentration-dependently suppressed adiponectin to almost non-detectable levels (to 9.8 +/- 0.03%, P = 0.0043), suggesting a strong humoral serum component of adiponectin down-regulation. This serum component is present in both obese and lean individuals with a tendency to a stronger effect in obese men and women. Separation by molecular size suggests that higher molecular weight (>30 kDa) fractions exert inhibition of adiponectin. Withdrawal of adipogenic ingredients from the culture medium also resulted in a decrease of adiponectin expression and secretion to 62.01 +/- 0.09% and 70.86 +/- 0.05%, respectively. We identified insulin as a critical component to maintain adiponectin expression with a down-regulation to 61.6 +/- 0.1% (P = 0.0011) in the absence of insulin. These dynamic changes of adiponectin expression and regulation with adipocyte differentiation are of physiological interest in the light of the paradoxical decrease of adiponectin levels and the continuous recruitment of preadipocytes for differentiation in obesity.     

Dual action of adiponectin on insulin secretion in insulin-resistant mice

Adiponectin is secreted by adipocytes and has been implicated as a mediator of insulin sensitivity. In this study, the acute effects of adiponectin on islets isolated from normal or diet-induced insulin resistant mice were examined. In normal islets, adiponectin (5 microg/ml) had no significant effect on insulin secretion. In contrast, in islets from mice rendered insulin resistant by high-fat feeding, adiponectin inhibited insulin secretion at 2.8 mM (P < 0.01) but augmented insulin secretion at 16.7 mM glucose (P < 0.05). The augmentation of glucose-stimulated insulin secretion by adiponectin was accompanied by increased glucose oxidation (P < 0.005), but without any significant effect on palmitate oxidation or the islet ATP/ADP ratio. Furthermore, RT-PCR revealed the expression of the adiponectin receptor AdipoR1 mRNA in mouse islets, however, with no difference in the degree of expression level between the two feeding groups. The results thus uncover a potential dual role for adiponectin to modify insulin secretion in insulin resistance.